For 2nd quarter FY 8/2026

Financial Results Presentation

Chordia Therapeutics Inc.

(TSE securities code: 190A)

April 14, 2026

Table of Contents

Corporate Overview and Business History

Company Profile

Name	Chordia Therapeutics Inc	**Establishment**	October,12,2017	**Head Office**	Fujisawa, Kanagawa, Japan	**Paid-in Capital**	¥1,128 million
Securities code	190A	**Representative**	Hiroshi Miyake	**Employees**	23 personnel (incl, 12 PhD)	**Total Funding Raised**	Approx. ¥10.4 billion

History

Foundation & Platform Establishment

Secured global exclusive rights to 4 programs from Takeda

Acceleration of Clinical Development

Initiated Phase 1 trial of rogocekib in Japan (60 patients enrolled)

Enrollment completed

rogocekib Expansion of Clinical Development

Initiation of expansion cohort in U.S. Phase 1/2 trial (Enrollment ongoing up to 42 patients)

Orphan Drug designation granted in the U.S.

No. of Patients Enrolled (Completed): JP : 60, US : 42

Established

2017 | 2018 | 2019 | 2022 | 2023 | 2024 | 2026

Milestones

Fundraising from Takeda and Venture Capital Firms

Listed on the TSE Growth Market

Total Funding Raised: ¥10.4 bn

Management Team Driving Growth with Diverse Expertise

- CEO and expert external directors driving growth through agile decision-making

Representative

CEO

Hiroshi Miyake

- Co-founded Chordia Therapeutics in October 2017; appointed as CEO
- Over 20 years in drug discovery at Takeda; Japan Site Head of Oncology, contributing to six clinical
- B.S. in Pharmaceutical Sciences, Osaka University; Ph.D. in Pharmaceutical Sciences, The University of Tokyo

External Director

Strategy

Manabu Nakamura
（Representative Director, Shinsei Capital Partners Co., Ltd）

External Director

Strategy

Yutaka Tsuchiya
（Former Representative Executive Officer of Eisai Co., Ltd.; External Director at Maruho Co., Ltd. ）

External Director

Strategy

Seiji Hirasaki
（Former Director, AnGes Inc.; Former President & CEO, Oriciro Genomics Inc. ）

Audit and Supervisor Committee member (External Director)

Accounting

Kosuke Ishii
（CPA／External Director, RaQualia Pharma Inc.）

R&D

Yukari Nishikata
（Former Head of Oncology Unit, Japan and Asia, Takeda Pharmaceutical Company Limited）

Law

Ayuko Hashimoto
（Attorney, Kotto-dori Law Office）

Table of Contents

Steady Progress in Both R&D and Corporate Activities

R&D

rogocekib

Clinical Trials
Total 102 patients enrollment Completed
In the U.S. and Japan

Global

rogocekib discovery research published in *ACS Medicinal Chemistry Letters*

Japan first-in-human trial for hematologic malignancies published in *Blood Advances*

Decision to Initiate Expanded Cohort
February 2026

CTX-439
GCN2

CTX-439 Joint Research with Kyoto University Paper Published March 2026

CTX-177

Termination agreement signed February 2026

Corporate Activities

Collaborative Research

Ongoing collaborations in ophthalmology with Senju Pharmaceutical and D. Western Therapeutics

IR Activities (Expansion of Communication and Engagement Opportunities)

Participation in Nikkei Tokyo Stock Exchange IR Fair 2025, Sapporo Stock Voice,
9th Asset Management EXPO, IR seminars for individual investors, investment study sessions, etc.

Profit or Loss as of 2nd quarter FY 8/2026

● **API and formulation-related costs decreased, resulting in lower costs compared to the same period last year.**

Unit：Million Yen

	Six months ended		
	Feb 2025 (Actual)	Feb 2026 (Actual)	Change
Revenue	**-**	**-**	**-**
Direct Expenses	-	-	-
R&D Expenses	799	510	△289
rogocekib (CTX-712)	624	318	△306
CTX-177	0	5	＋5
CTX-439	11	3	△8
Other (incl. personnel expenses)	163	186	＋23
Other G&A Expenses	196	152	△44
Operating Loss	**△996**	**△662**	
Non-operating Income	23	51	＋28
Non-operating Expenses	2	21	＋19
Loss Before Income Taxes	**△975**	**△632**	**＋343**
Income Taxes	1	0	△0
Net Loss	**△976**	**△633**	**＋343**

Key Points for 2nd quarter FY8/2026

● **rogocekib: CTX-712（CLK)：**

- In the U.S. Phase 1/2 clinical trial, 6 additional patients have been enrolled, bringing the total to 42 patients.
- Impact of reduced API and formulation-related costs (¥329 million) in the current fiscal year.

● **Other G&A Expenses：**

- Impact of decreased patent-related costs.

Balance Sheet as of 2nd quarter FY 8/2026

● **Exercise of the 9th series of stock options is progressing steadily, ensuring sufficient cash balance (development funds).**

Unit：Million Yen

	Aug 31, 2025 (Actual)	Feb 28, 2026 (Actual)	Change
Current Assets	**2,669**	**2,500**	△169
Cash and deposits	2,548	2,447	△101
Others	121	52	△69
Non-current Assets	**12**	**12**	-
Total Assets	**2,681**	**2,512**	△169
Current Liabilities	**244**	**197**	△47
Non-current Liabilities	-	-	-
Total Liabilities	**244**	**197**	△47
Total Net Assets	**2,437**	**2,315**	△122
Total Liabilities and Net Assets	**2,681**	**2,512**	△169

Key points for 2nd quarter FY8/2026

- **Current Assets / Net Assets:：**
  - Impact of ¥499 million proceeds from stock option exercises against ¥611 million expenditures from operating activities.

Table of Contents

Of the five pipelines, two are in the clinical stage

— Strategic focus on rogocekib, which has high market potential, to accelerate value creation

- Concentrate resources on rogocekib to pursue accelerated approval in Japan and the U.S.
- Assess monetization opportunities for other pipelines (CTX-177/CTX-439/GCN2) via out-licensing

	Target	Code	Common name	Target cancer type	Development stage	Current assumed options
①	CLK	CTX-712	rogocekib	Acute myeloid leukemia, myelodysplastic syndrome, ovarian cancer, and more	Ph1 in JP completed, Ph1/2 in US are ongoing	Accelerated approval JP: In-house commercialization US: License Out
②	MALT1	CTX-177		Lymphoma	P1 clinical trials	License out
③	CDK12	CTX-439		Solid tumors	Pre-clinical trials have been complete	License Out
④	GCN2	None		Solid tumors, hematological tumors	Pre-clinical trials	License Out
⑤	Undisclosed	None		Solid tumors, hematological tumors	Pre-clinical trials	To be determined

Development Milestones for rogocekib

— Steady Progress with 102 Patient Enrollments Across Japan and the U.S.

- **Based on the principles of FDA's "Project Optimus," we are revising the development schedule to optimize dosing for improved safety and efficacy, enhance quality, and maximize clinical value post-approval.**
- **Patient enrollment in clinical trials is progressing steadily, with 102 patients already enrolled across Japan and the U.S., receiving Orphan Drug designation from the FDA.**

Achievements as of February 2026

- ✓ 2026/ February 102 patients enrolled in Japan and the U.S.
- ✓ 2026/ February Decision to Initiate Expanded Cohort

Future best-case milestones (Note)

- ☐ 2026-Mid Interim Phase 1 results for rogocekib U.S. clinical trial announced
- ☐ 2027-Mid Initiation of Phase 2 trials for rogocekib in Japan and the U.S.
- ☐ 2028/ 2H Marketing authorization application for rogocekib



(Note) Based on the assumption that the clinical trials will proceed as we expect, and if the necessary clinical data cannot be collected as we expect, or if for some reason the next clinical trial is not conducted or an application for approval is not filed even though the clinical data has been collected, or if it takes time before the next clinical trial is conducted, may be conducted at a different time than stated, or may not be conducted at all.

Rogocekib CTX-712 (CLK) : Initiation of expansion cohort

Objectives of expansion cohort

Determine recommended dose and target indications based on safety and efficacy evaluation



Monetization Strategy and Focus

—Strategy (shortened timelines) × Focus (small molecules, first-in-class, precision)

- Accelerated value creation by shifting focus from discovery to clinical research, significantly shortening development timelines
- Risk reduction and higher returns through small molecules (low manufacturing risk), first-in-class (global novelty), and precision medicine (higher success probability)
- Development capabilities comparable to major pharmaceutical companies (50% PhD holders) driving execution



Diversified Capital Strategy under Uncertainty

- As clinical data accumulates in Japan and the U.S. (reducing risk and uncertainty while increasing value), a broader range of capital strategy options becomes available.



Challenging the Global Market
— Chordia's Global Expansion and the AML Market

- Chordia aims to commercialize rogocekib in the United States, the world's largest pharmaceutical market.
- FDA approval is expected to facilitate accelerated regulatory review through reliance mechanisms in multiple countries, including Singapore, South Korea, Taiwan, Malaysia, Australia, and Saudi Arabia, thereby accelerating global expansion.



(1) Data as of 2020 (GlobalData 2020)
(2) Data for 2023 (JPMA Data Book 2025)

Table of Contents

Prioritized business goals for FY2026

Clinical trial progress for approval of rogocekib (CTX-712)

- Initiation of expansion cohort in U.S. Phase 1/2 trial to accelerate enrollment
- Interim Phase 1 results presented at a major international conference, supporting trial advancement

Progress

Initiation of expansion cohort (first patient dosed)

Preparation for interim presentation at the EHA is progressing

Proactively engage in new business alliances

CTX-177 is a priority for re-licensing and actively advanced. Leveraging CTX-712, we continue partnership discussions for CTX-439, GCN2, and other programs globally. Business discussions are ongoing, with timely disclosure upon completion.

Progress

Ongoing out-licensing activities across pipeline programs

Termination agreement signed for CTX-177

Properly execute disclosure to shareholders

Research progress will be disclosed at domestic and international conferences (≥1 presentation annually). Investor communication is a key priority, including seminars and CEO messaging via media channels.

Progress

Participation in retail investor seminars and IR events

Publication of analyst reports on the website

Key Focus Areas Going Forward

- Decision to Initiate Expanded Cohort
- CTX-177 Termination agreement signed
- Publication of chemistry paper on compound discovery
- Publication of P1 clinical results in Japan (hematologic malignancies)
- Investigator meeting held at the ASH Annual Meeting

Key Updates

- Initiation of expansion cohort (first patient dosed)
- Publication of collaborative research results with Kyoto University on CTX-439 (CDK12 inhibitor)

- U.S. Phase 1 interim results (presentation at EHA, June planned)
- Aiming for Orphan Drug designation in Japan (timing TBD)

Management policies and 2030 vision

Building a world where tomorrow is another day!

Delivering the world's first made-in-Japan new anticancer drugs to patients as soon as possible

Mission

We are passionate to deliver first-in-class cancer drugs to patients.

2030 Vision

To be an R&D-oriented pharmaceutical company based in Japan.

Our disclosure policy

- **Chordia will release information only after receiving permission from the academic societies for the presentation of data, etc., and will disclose information appropriately**
- **Based on fair disclosure, Chordia will not respond to individual questions**
- **Chordia will promptly provide answers to received questions through IR and update the "IR Frequently Asked Questions" page on our website in a timely manner**

Disclaimer

- This presentation has been prepared solely for the purpose of presenting relevant information regarding Chordia Therapeutics Inc. (the “Company” or “Chordia”). This presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in Japan, the United States or any other jurisdictions.
- The information contained herein is based on current economic, regulatory, market trends and other conditions. The Company makes no representation or guarantee with respect to the credibility, accuracy or completeness of the information herein. The information contained herein may change without prior notice. You may not publish or use this presentation and the contents thereof for any other purpose without prior written consent of the Company. Furthermore, the information on future business results are forward-looking statements. Forward-looking statements include but are not limited to expressions such as “believe,” “expect,” “plan,” “strategic,” “anticipate,” “predict” and “possibility,” as well as other similar expressions to explain future business activities, achievements, events and future conditions. Forward-looking statements are predictions about the future that reflect management’s judgment based on currently available information. As such, these forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the forward-looking statements. Therefore, you may not rely entirely on forward-looking statements. The Company does not assume any obligation to change or correct any forward-looking statements in light of new information, future events or other findings. This presentation contains statements that constitute forward-looking statements, including estimations, forecasts, targets and plans. Such forward-looking statements do not represent any guarantee by management of future performance. Any forward-looking statements in this presentation are based on the current assumptions and beliefs of the Company in light of the information currently available to it, and involve known and unknown risks, uncertainties and other factors. Such risks, uncertainties and other factors may cause the Company’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking information.
- This presentation and its contents are confidential and are being provided solely for informational purposes and may not be retransmitted. This presentation is being furnished solely for informational purposes and may not be reproduced or redistributed to any other person. In giving this presentation, the Company does not undertake any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent.
- Information on companies other than the Company and information provided from third parties are based on public information or sources. The Company has not independently verified the accuracy and appropriateness of such data and indicators used herein, nor does the Company assume any responsibility for the accuracy and appropriateness of such data and indicators presented in this presentation.
- This presentation does not contain all relevant information relating to the Company and the securities and is qualified in its entirety by reference to the detailed information appearing in the Japanese language prospectus (the “Japanese Prospectus”). Any investment decision with respect to the securities should be made solely upon the basis of the information contained in the Japanese Prospectus.


Chordia
Therapeutics